LRRK2 and Parkinson disease: Consistent with this observation that MEK/ERK signaling is implicated in PD-related pathological alterations, pharmacological inhibition of MEK1/2 kinase activity rescued the inflammatory profile of LRRK2 G2019S astrocytes and attenuated cytokine secretion (Fig. 5).